Want to join the conversation?
$PXD 2Q15 Call: We had a net loss attributable to PXD of $218MM or $1.46 per diluted share, that did include noncash mark-to-market derivative losses of $222. Adjusted income excluding noncash mark-to-market derivative losses and unusual items (Raton restructuring charges and closure of Denver office), we were at $15MM or $0.10 of earnings.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.